Homology Medicines, Inc. (FIXX) Social Stream
HOMOLOGY MEDICINES INC (FIXX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering HOMOLOGY MEDICINES INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-15 | 6 | $30.001 | $8 | $23 | $1.17 | 1865.81% |
| 2022-01-31 | 6 | $30 | $8 | $22 | $1.17 | 1780.34% |
| 2022-02-22 | 8 | $30 | $8 | $23.4 | $1.17 | 1900% |
| 2022-03-25 | 8 | $29 | $8 | $16.2 | $1.17 | 1284.62% |
| 2022-03-30 | 8 | $29 | $4 | $15.4 | $1.17 | 1216.24% |
| 2022-05-16 | 8 | $29 | $4 | $14 | $1.17 | 1096.58% |
| 2022-08-13 | 8 | $29 | $4 | $13.833 | $1.17 | 1082.31% |
| 2022-08-22 | 8 | $20 | $4 | $10.166 | $1.17 | 768.89% |
| 2022-09-17 | 9 | $20 | $4 | $10 | $1.17 | 754.7% |
| 2022-11-11 | 9 | $20 | $3 | $9 | $1.17 | 669.23% |
| 2022-11-17 | 8 | $20 | $3 | $8.75 | $1.17 | 647.86% |
| 2023-02-08 | 9 | $20 | $3 | $8.75 | $1.17 | 647.86% |
| 2023-03-12 | 8 | $20 | $2 | $8.375 | $1.17 | 615.81% |
| 2023-03-16 | 9 | $20 | $2 | $8.375 | $1.17 | 615.81% |
| 2023-05-15 | 9 | $20 | $2 | $8.571 | $1.17 | 632.56% |
| 2023-06-06 | 9 | $20 | $2 | $8.666 | $1.17 | 640.68% |
| 2023-07-28 | 2 | $7 | $1.5 | $4.375 | $1.17 | 273.93% |
The Trend in the Analyst Price Target
FIXX's average price target has moved down $29 over the prior 39 months.
FIXX reports an average of 493.49% for its upside potential over the past 37 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-09 | 8 | 20 | 2.0 | 8.375 | 1.34 | 525% |
| 2023-03-16 | 9 | 20 | 2.0 | 8.375 | 0.98 | 754.59% |
| 2023-06-06 | 8 | 20 | 2.0 | 8.666 | 1.04 | 733.27% |
| 2023-07-28 | 3 | 6 | 1.5 | 3.500 | 1.33 | 163.16% |
| 2023-07-28 | 4 | 7 | 1.5 | 4.375 | 1.33 | 228.95% |
FIXX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3 | 0 | 0 | 2 | 0 | 0 | 2 |
The Trend in the Broker Recommendations
Over the past 18 months, FIXX's average broker recommendation rating worsened by 1.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how HOMOLOGY MEDICINES INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -2486.14% of that group.
- FIXX has a higher upside potential (average analyst target price relative to current price) than 2543.73% of all US stocks.
- HOMOLOGY MEDICINES INC's number of analysts covering the stock is greater than 2129.31% of stocks in the small market cap category.
- In terms of how HOMOLOGY MEDICINES INC fares relative to Healthcare stocks, note that its average analyst price target is higher than 523.25% of that group.
Stocks similar to HOMOLOGY MEDICINES INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are BTAI, MBIO, and ACET.
View All Top Stocks by Price Target
Is FIXX a Buy, Hold or Sell? See the POWR Ratings now!